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Abstract Mamba intestinal toxin (MIT1) isolated from Den-
droaspis polylepis venom is a 81 amino acid polypeptide cross-
linked by five disulphide bridges. MIT1 has a very potent action
on guinea-pig intestinal contractility. MIT1 (1 nM) potently
contracts longitudinal ileal muscle and distal colon, and this
contraction is equivalent to that of 40 mM K+. Conversely MIT1
relaxes proximal colon again as potently as 40 mM K+. The
MIT1-induced effects are antagonised by tetrodotoxin (1 WM) in
proximal and distal colon but not in longitudinal ileum. The
MIT1-induced relaxation of the proximal colon is reversibly
inhibited by the NO synthase inhibitor L-NAME (200 WM). 125I-
labelled MIT1 binds with a very high affinity to both ileum and
brain membranes (Kd = 1.3 pM and 0.9 pM, and Bmax = 30 fmol/
mg and 26 fmol/mg, respectively). MIT1 is a very highly selective
toxin for a receptor present both in the CNS and in the smooth
muscle and which might be an as yet unidentified K+ channel.
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1. Introduction
Mamba venoms contain an unusually high diversity of
pharmacologically active peptides [1]. Two particularly impor-
tant structural groups have been identi¢ed so far. The ¢rst
group comprises a series of toxins homologous to the basic
pancreatic trypsin inhibitor. They are the dendrotoxins which
are powerful blockers of some of the Kv1,n class of K chan-
nels and display a strong central neurotoxicity [2^8]. Besides
dendrotoxins and other protease inhibitors with a weaker ac-
tivity on K channels, this same structural class comprises
calcicludins which are blockers of high voltage activated
Ca2 channels with a particular potency for L-type Ca2
channels in cerebellar granule neurones [9]. The second struc-
tural group contains peptides which are structural homo-
logues to curaremimetic K-neurotoxins. This structural group
comprises short and long K-neurotoxins which block the
nicotinic receptor, muscarinic toxins which act selectively as
agonists or antagonists on one or several of the muscarinic
receptor types [10^12], anticholinesterase toxins [13,14],
‘angusticeps-type’ peptides with low toxicity and unknown
molecular targets, and calciseptins which are speci¢c blockers
of L-type Ca2 channels mainly in the cardiovascular system
[15]. The remaining group of peptides contained in mamba
venoms is heterogeneous both in peptide size and in structural
arrangement if known at all. The function of most peptides in
this latter class has not yet been elucidated.
This paper deals with a peptide belonging to this latter
relatively unexplored class of peptides. The toxin named
mamba intestinal toxin 1 (MIT1) is a polypeptide with 81
amino acids and ¢ve disulphide bridges. The solution struc-
ture of MIT1 has been recently determined at a resolution of
0.5 Aî and has revealed a new type of folding for venom toxins
similar to that of colipase, a protein involved in fatty acid
digestion [16]. We show that MIT1 has the unique property
of contracting guinea-pig ileum and distal colon while relaxing
the proximal colon. MIT1 has very high a⁄nity binding sites
in membranes from both guinea-pig ileum and rat brain,
which appear to be unique to this toxin.
2. Materials and methods
2.1. Puri¢cation of MIT1 and sequence determination
MIT1 was puri¢ed from the venom of the black mamba Dendroas-
pis polylepis as previously described (fraction G4 from Fig. 1 in [17]).
The primary structure of MIT1 was determined by Edman degrada-
tion of the complete polypeptide using an Applied Biosystems model
477 A microsequencer. The polypeptide was reduced with 2-mercap-
toethanol and pyridylethylated with 4-vinylpyridine before sequenc-
ing. The C-terminal part of the polypeptide was obtained by splitting
at Met-55 with BrCN (MIT1 was incubated for 24 h at room temper-
ature with 0.1 mg/ml BrCN in 70% formic acid) and separation on a
microbore C18 reverse phase column. The C-terminal amino acid was
con¢rmed by digestion with carboxypeptidase. A spontaneous hydro-
lysis of the C-terminal serine was observed. Lasermat mass spectros-
copy shows the progressive disappearance of the peak at 8607 Da and
concomitant appearance of a peak at 8506 Da. The molecular weight
determined by electrospray ionisation mass spectrometry yielded a
value of 8506.4, in accordance with the value deduced from the se-
quence determination (8506.9) for the polypeptide MIT1 without the
C-terminal serine. MIT1 is very similar to the polypeptide ‘protein A’
puri¢ed from the same venom [26], the main di¡erence being the
inversion of cysteine 18 with serine 22 which may be due to a previous
error in the sequence determination. Lysine 55 is deleted in MIT1 and
the labile C-terminal serine is absent in protein A.
2.2. Toxicity measurements
They were carried out as previously described [18].
2.3. Contraction measurements on isolated organs
Adult guinea-pigs were killed by decapitation. Samples of longitu-
dinal muscle of the ileum were taken by pinching and stretching the
ileum in the vicinity of the caecum. Pieces of proximal colon were cut
o¡ in the vicinity of the caecum and pieces of distal colon in the
vicinity of the rectum. All pieces were cut 1.5 cm long and mounted
vertically in 3 ml organ baths ¢lled with a Tyrode medium containing
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137 mM NaCl, 2.7 mM KCl, 1 mM MgSO4, 0.5 mM NaH2PO4, 12
mM NaHCO3, 1.8 mM CaCl2 and 5 mM glucose. This medium was
oxygenated by carbogen. Adult rats were killed by decapitation. Their
hearts and thoracic aortas were immediately excised and dissected in
the above medium for aorta and for heart in Tyrode medium con-
taining 127 mM NaCl, 4 mM KCl, 1 mM MgSO4, 0.5 mM NaH2PO4,
12 mM NaHCO3, 1.8 mM CaCl2 and 5 mM glucose which was also
oxygenated by carbogen. Right and left atria were mounted vertically
in the 3 ml baths as well as rings of de-endothelialised aorta. The
media were thermostatted at 37‡C. Strips and organs were ¢xed to
a UL5 microbalance screwed to a UC2 isometric force transducer
which was connected to a model -50 ampli¢er. Tensions were recorded
on a Gould 2600 polygraph. Initial preloads were 0.5 g for intestine
strips, 1 g for atria and 2 g for aorta rings. Left atria were stimulated
at 1 Hz through ¢eld electrodes using square wave pulses of 2 ms and
a voltage which was 50% above threshold.
2.4. Iodination
MIT1 was iodinated by the iodogen method. MIT1 (0.5 nmol) was
incubated for 15 min at room temperature with 0.5 nmol (1 mCi) of
125INa (Dupont-NEN) in 40 Wl of 100 mM Tris-HCl pH 7.4 in an
Eppendorf tube coated with 3 nmol iodogen. The reaction was
stopped by addition of 400 Wl of 1 mg/ml bovine serum albumin
(BSA) in 0.1% tri£uoroacetic acid (solvent A). BSA and free iodine
were removed by a chromatographic step on a Symmetry C18
(4.6U250 mm) Waters column. With a gradient from 10% to 40%
of solvent B (0.1% tri£uoroacetic acid in acetonitrile) in 30 min,
125I-MIT1 eluted as a thin single peak at 22.5 min, the maximum of
radioactivity being superimposed on the maximum of absorbance.
Assuming that all the radioactivity found in this peak has been in-
corporated in 0.5 nmol of MIT1, we evaluated the speci¢c radioactiv-
ity as 1639 cpm/fmol.
2.5. Binding to membranes
Membranes used were P3 pellets obtained by homogenisation
and di¡erential centrifugations of whole rat brain and guinea-pig
ileum smooth muscle obtained by removing the epithelium by scratch-
ing. Incubations and ¢ltrations were done as described earlier [9]
but in 20 mM Tris-HCl pH 7.4 with 1 mg/ml BSA as incubation
medium.
2.6. Electrophysiological measurements of cloned K+ channels
expressed in Xenopus oocytes
Cloning of cDNAs, synthesis of complementary RNAs, preparation
of oocytes, cRNA injections and electrophysiological measurements
have been previously described [19].
2.7. Patch-clamp recording of cloned K+ channels expression in
transfected COS cells
COS cells were grown and transfected as described earlier [19].
Cloning of cDNA and subcloning in plasmid have been detailed in
[20,21]. Electrophysiological measurements on COS cells were per-
formed 48 h after the transfection using the whole cell con¢guration
of the patch-clamp technique. For K channel recordings, the pipette
solution contained KCl 150 mM, MgCl2 3 mM, EGTA 5 mM,
HEPES-KOH 10 mM, pH 7.4. The external solution contained KCl
5 mM, NaCl 150 mM, CaCl2 1 mM, MgCl2 3 mM, HEPES-NaOH
10 mM, pH 7.4. For proton-gated Na channels, the pipette solution
contained KCl 140 mM, MgCl2 2mM, CaCl2 1.8 mM, HEPES-NaOH
10 mM, pH 7.4.
3. Results
3.1. Primary structure and toxicity of MIT1
MIT1 is a 81 amino acid polypeptide with 10 cystine resi-
dues which form ¢ve disulphide bridges. The primary struc-
ture of MIT1 is: A V I T G A C E R D L Q C G K G T C C
A V S L W I K S V R V C T P V G T S G E D C H P A S H
K I P F S G Q R M H H T C P C A P N L A C V Q T S P K
K F K C L S K S. The solution structure has recently been
determined and shows that MIT1 does not belong to any class
of proteins isolated from snake venoms so far [16].
Intraperitoneal injection of MIT1 in mice (5^10 Wg/g body
weight) produced only transient e¡ects. Injected mice had
their hind legs stretched out and lacked muscle tone for about
1 h before they recovered a normal motion. Intracisternal
injection of MIT1 at 0.8 Wg/g body weight induced small
bounds for less than 2 h. At higher doses (1.6^5 Wg/g), animals
again had their hind legs stretched out and lacked muscle
tone, but these e¡ects lasted more than 17 h and were asso-
ciated with a reduced motion.
Fig. 1. E¡ect of MIT1 on the contractility of guinea-pig ileum longi-
tudinal muscle. A: Contractions of ileum longitudinal muscle by in-
creasing the external K concentration to 40 mM and by 1 nM
MIT1. B: Concentration-response curve of guinea-pig ileum longitu-
dinal muscle contraction obtained with MIT1. Results are given as
% of the maintained contraction obtained with 40 mM K. W:
wash. The data are mean values from two to eight experiments.
Fig. 2. E¡ect of MIT1 on the contractility of guinea-pig colon. A:
Relaxation of proximal colon induced by 40 mM K or 1 nM
MIT1. B: Contraction of distal colon induced by 40 mM K or
1 nM MIT1. The data presented are representative of six to eight
experiments.
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3.2. Physiological experiments
MIT1 has a very potent contractile e¡ect on guinea-pig
ileum longitudinal muscle. Fig. 1A shows that 1 nM MIT1
contracts this muscle as strongly as 40 mM K. However, the
e¡ect is transient while contraction evoked by K is sustained.
A concentration-response curve of this e¡ect is shown in Fig.
1B. The ED50 is 0.3 nM. At the same low concentration of
1 nM, MIT1 has a di¡erential e¡ect on whole strips of colon.
It relaxes proximal colon (Fig. 2A) but contracts distal colon
(Fig. 2B). Fig. 2 also shows the di¡erence in the e¡ect of
40 mM K in the proximal and distal colon. In the proximal
colon, K induced a relaxation followed by a slow increase in
the tone (Fig. 2A) whereas it produced a maintained contrac-
tion in the distal colon (Fig. 2B).
In order to identify the target of MIT1 in the intestine and,
in particular, to separate presynaptic from postsynaptic ef-
fects, the e¡ects of tetrodotoxin (TTX) were analysed. TTX
(1 WM), which is known to block action potential propagation
[22], had no e¡ect on the MIT1-induced contraction in the
longitudinal muscle from guinea-pig ileum (not shown). In
contrast, both the relaxing e¡ect of MIT1 in the proximal
colon (Fig. 3Aa) and the contracting e¡ect of MIT1 in the
distal colon (Fig. 3Ab) were inhibited in the presence of TTX
(1 WM), indicating that a major part of the toxin action takes
place presynaptically. The relaxing e¡ect of MIT1 was further
investigated by using the Ca2-dependent K channel blocker
apamin and the nitric oxide (NO) synthase inhibitor L-NG-
nitroarginine methyl ester (L-NAME). Apamin (1 nM) had
no e¡ect (not shown) whereas L-NAME (200 WM) reversibly
antagonised the MIT1-induced relaxation (Fig. 3B). The
MIT1-induced contraction of longitudinal ileum or distal co-
lon was abolished by methoxyverapamil (D600, 10 WM), sug-
gesting the involvement of Ca2 entry through voltage-de-
pendent Ca2 channels as a component of the MIT1 e¡ect
(Fig. 4). The contracting e¡ect of MIT1 was inhibited when
the tone was previously raised by 60 mM external K and was
abolished in the presence of K channel openers (cromakalim
or pinacidil, 10 WM; Fig. 4).
Although it has a potent action on the intestine, MIT1
appears to be inactive on the cardiovascular system. At a
concentration of 0.2 WM, it neither contracts de-endothelial-
ised rat thoracic aorta nor relaxes aorta precontracted with 40
mM K. At the concentration of 0.1 WM it does not a¡ect the
contractions of left and right rat atria (not shown).
3.3. Binding experiments
125I-MIT binds with a very high a⁄nity to speci¢c receptors
in ileum and brain membranes. Fig. 5 shows the saturation
curves and the Scatchard plots corresponding to these binding
experiments. Binding parameters are: Kd = 1.3 pM and
Bmax = 30 fmol/mg for guinea-pig ileum longitudinal muscle
membranes (Fig. 5A) and Kd = 0.9 pM and Bmax = 26 fmol/
mg for rat brain membranes (Fig. 5B).
Competition experiments with the unlabelled toxin con¢rmFig. 3. Inhibition of MIT1 e¡ects. A: E¡ect of TTX (1 WM, right
panels) on the relaxation of proximal colon induced by 40 mM K
or 1 nM MIT1 (a) and on the contraction of distal colon induced
by 40 mM K or 1 nM MIT1 (b). Control experiments obtained
before TTX application are also shown (left panels). B: E¡ect of L-
NAME (200 WM) on relaxation of proximal colon induced by 1 nM
MIT1. Control experiments obtained before application and after re-
moval of L-NAME are also shown. The data presented are repre-
sentative of at least four to eight experiments.
Fig. 4. E¡ect of the L-type voltage-dependent Ca2 channel antago-
nist D600 (10 WM), the K channel openers cromakalim (10 WM)
and pinacidil (10 WM) and increased external K concentration (60
mM) on the contraction induced by (1 nM) MIT1 on guinea-pig
longitudinal ileum muscle (A) and guinea-pig distal colon (B). Each
condition is expressed as a percentage of the maintained contraction
induced by 40 mM K. Results are expressed as mean values of
four to eight experiments.
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the existence in both ileum and brain membranes of high
a⁄nity speci¢c binding sites in the picomolar range (Fig. 6).
At a low concentration (3.3 pM), 125I-MIT1 binds to guinea-
pig ileum with a K0:5 value of 3.7 pM (Fig. 6A) corresponding
to a Kd of 1.2 pM, almost identical to the value obtained from
the Scatchard plot (1.3 pM). In rat brain, the K0:5 value is
4 pM (Fig. 6B), corresponding to a Kd value of 1 pM, also
very close to the Kd of 0.9 pM obtained from the Scatchard
plot.
3.4. Electrophysiological measurements
MIT1 was tested for possible activity against outward volt-
age-sensitive K channels (Kv channels) expressed in Xenopus
oocytes or in COS cells. None of the cloned channels Kv1.1,
Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv2.1, Kv3.4 expressed in Xen-
opus oocyte was a¡ected by 100 nM MIT1 (n = 2 or 3 for each
condition). Similarly, neither the cloned cardiac channels
Kv4.2, HERG nor the human KCNQ1 channel coexpressed
with IsK [21,23] nor KCNQ2 and KCNQ3 nor the two P
domains K channel TREK-1, TASK-1 and TRAAK
[20,24] recorded in COS transfected cells were a¡ected by
100 nM MIT1. Inward recti¢er K channels such as IRK1,
IRK2, ROMK1, and the heteropolymers of G-protein-gated
inward recti¢ers GIRK1,2 and GIRK1,4 were also tested.
These cloned channels expressed in Xenopus oocytes were
also insensitive to 100 nM MIT1 (n = 2 or 3 for each channel
type).
MIT1 was also tested against the proton-gated Na chan-
nels ASIC 1a, ASIC 2a and ASIC 3 that are involved in
sensing tissue acidosis [25]. None of these channels, trans-
fected in COS cells, was sensitive to 100 nM MIT1.
4. Discussion
The results of this study show that MIT1 is a polypeptide
toxin that has a potent e¡ect on intestinal contractility. MIT1
at an extremely low concentration (0.1 nM) relaxes proximal
colon whereas it contracts distal colon and longitudinal ileal
muscle. A particularly interesting aspect of MIT1 is that it is a
toxin with a new type of folding. Its overall three-dimensional
structure resembles that of colipase [16] although there is only
20% sequence homology between the two structures. Unlike
colipase, MIT1 does not activate lipase and unlike MIT1,
colipase, even at the high concentration of 10 WM, does not
have any e¡ect on intestinal contraction (not shown).
The MIT1-induced relaxation was inhibited by TTX, sug-
gesting that the toxin stimulates inhibitory enteric neurones.
Recent studies have suggested that neural inhibition of con-
traction in the gastrointestinal tract involved at least two
transmitter substances. NO was clearly identi¢ed as one of
the inhibitory neurotransmitters [27^29]. NO is synthesised
and released during stimulation of inhibitory nerves. Postjunc-
tional mechanisms involving smooth muscle guanylate cyclase
transduce the inhibitory transmitter signal to produce cyclic
GMP-dependent membrane hyperpolarisation through open-
ing of the K channel and inhibition of the contraction. Other
transmitter substances mediate nerve-evoked inhibition of
contraction through a NO-independent pathway, by activa-
Fig. 5. Binding of 125I-MIT1 to ileum and brain membranes. Mem-
branes were incubated in 5 ml of the bu¡er with 125I-MIT1 (0.1^3
pM) for 2 h at 25‡C. Insets: Saturation curves for 125I-MIT1 bind-
ing (a) obtained after subtraction of non-speci¢c 125I-MIT1 binding
(F) (determined by including 2 nM MIT in the incubation medium)
from the total 125I-MIT1 binding (E). Main panels: Corresponding
Scatchard plots (a). Results are means of two determinations.
Bound/free is expressed as pmol/mg of proteinUnM. A: Guinea-pig
ileum membranes (32 Wg/ml). B: Rat brain membranes (42 Wg/ml).
Fig. 6. Concentration-response curves for the inhibition by MIT1 of
125I-MIT1 binding to guinea-pig ileum and rat brain membranes.
The unlabelled peptide was ¢rst incubated at di¡erent concentra-
tions with the membranes (65 Wg/ml) in 2 ml bu¡er and then 125I-
MIT1 was added and the membranes were incubated for 3.5^5 h at
22^23‡C. A: Guinea-pig ileum membranes with 3.3 pM of 125I-
MIT1. B: Rat brain membranes with 3.4 pM of 125I-MIT1. b :
MIT1.
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tion of apamin-sensitive K channels [30]. Both NO-depend-
ent and apamin-sensitive components of hyperpolarisation
may then contribute to the closing of voltage-dependent
Ca2 channels, leading to a decrease in intracellular Ca2
levels and relaxation of smooth muscle. It is also likely that
membrane potential-independent mechanisms, such as an in-
hibition of myosin light chain kinase leading to a decrease in
the sensitivity of the contractile apparatus to Ca2 or an in-
creased uptake or extrusion of Ca2, contribute to nerve-
evoked inhibition of contractions [31]. The absence of e¡ect
of apamin and the inhibition of the MIT1-induced relaxation
by the NO synthase inhibitor L-NAME suggest that MIT1
indirectly relaxes proximal colonic muscle by stimulating the
release of NO from inhibitory enteric neurones.
Although the absence of e¡ect of TTX on the contracting
e¡ect of MIT1 in ileum suggests that the toxin might act
directly on smooth muscle cells in this part of the gut, TTX
inhibition of the MIT1-induced contraction in distal colon
clearly indicates the involvement of an excitatory neural com-
ponent. The excitatory neurotransmitter involved remains to
be identi¢ed as antagonists of muscarinic, serotoninergic or
substance P receptors did not a¡ect the MIT1-induced con-
traction (not shown).
The identi¢cation of 125I-MIT1 binding sites in both ileum
and brain membranes supports the idea that these toxin re-
ceptor sites are located both pre- and postsynaptically. Di¡er-
ences in a⁄nities measured by binding experiments with 125I-
MIT1 on the one hand, and evaluated from contraction stud-
ies on the other hand, are quite usual in the toxin ¢eld. They
are probably due to the fact that binding is made on non-
polarised membranes which have their two faces exposed to
the same ionic medium, whereas pharmacological data are
obtained in intact tissue and relate to toxin action on a re-
ceptor being part of a cell with a polarised membrane poten-
tial and with di¡erent ionic conditions on both faces of the
membrane. In addition we know very little about the di¡usion
properties of the toxins to reach their target in ileum longi-
tudinal muscle and distal colon.
A particularly interesting property of animal toxins is that
they often have endogenous equivalents. The best known case
is that of sarafotoxins for which the endogenous equivalents
are the endothelins [32]. However, there are many other cases.
For instance, the atrial natriuretic factor has an equivalent in
the green mamba venom [33] and conversely the bee venom
K channel toxins apamin and mast cell degranulating pep-
tide seem to have endogenous equivalents in the brain [34,35].
Therefore, there might also be an endogenous equivalent of
MIT1 in mammals. None of the intestinal e¡ectors (or their
antagonists) which have been tested has an action like MIT1
and none of them binds to the MIT1 receptor. Therefore it is
to be expected that if such an endogenous compound exists it
will be a new important peptide for the control of intestinal
motility. Tools which have been developed in this work
should facilitate the search of such new and physiologically
important molecules.
The physiological data which show that MIT1 in the pres-
ence of TTX has the same e¡ects as increasing the external
K concentrations lead to the idea that the high a⁄nity bind-
ing site through which MIT1 exerts its action might be a K
channel, although the opening of non-selective cation chan-
nels or voltage-gated Ca2 channels cannot be completely
eliminated. The putative K conductance involved in MIT1
action would be a K channel with a very high a⁄nity for the
toxin. This particular channel would be in a relatively low
concentration in brain membranes (V25 fmol/mg). Electro-
physiological experiments have shown that MIT1 does not act
on the following K channels at low concentration: Kv1.1,
Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv2.1, Kv3.4, Kv4.2, TREK-1,
HERG, human KCNQ1 coexpressed with IsK, KCNQ2,
KCNQ3, IRK1, IRK2, ROMK1, GIRK1,2 and GIRK1,4.
However, there are more than 60 di¡erent genes for K chan-
nels that have now been cloned and many more are probably
to come. Therefore, the search should continue for the molec-
ular identi¢cation of the MIT1 target. It might have a partic-
ularly high importance for the physiology and physiopathol-
ogy of the intestinal system since MIT1, this new peptide with
a new structure, has limited action when injected into the
central nervous system and essentially no action on vascular
smooth muscle or cardiac systems.
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